[Effect of protein kinase C on human melanoma A375-S2 cell death induced by evodiamine]

Che Wang1, Min-wei Wang, Shin-ichi Tashiro

  • 1China-Japan Research Institute of Medical and Pharmaceutical Sciences.

Abstract

Insights

Evodiamine induces apoptosis in A375-S2 cells by inhibiting protein kinase C (PKC), which regulates ERK and Bcl-2 expression, leading to cell death.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Pharmacology

Background:

  • Evodiamine is a natural compound with potential anti-cancer properties.
  • Understanding the molecular mechanisms of evodiamine's action is crucial for its therapeutic development.

Purpose of the Study:

  • To investigate the role of protein kinase C (PKC) in evodiamine-induced apoptosis of A375-S2 cells.
  • To elucidate the relationship between PKC, ERK, and Bcl-2 in this process.

Main Methods:

  • TUNEL assay to quantify apoptosis.
  • MTT assay for cytotoxic effect assessment.
  • Western blotting to analyze protein expression (ERK, phospho-ERK, Bcl-2).

Main Results:

  • Evodiamine treatment induced apoptosis in A375-S2 cells.
  • PKC inhibition (staurosporine) and ERK inhibition (PD98059) enhanced evodiamine-induced cell death.
  • Evodiamine inhibited PKC activity and down-regulated ERK, phospho-ERK, and Bcl-2 expression.

Conclusions:

  • PKC acts upstream of ERK and Bcl-2 in the evodiamine-induced cell death pathway.
  • These findings highlight PKC as a key mediator in evodiamine's anti-cancer effects.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...